Arcturus Therapeutics Holdings/$ARCT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
- Ticker
- $ARCT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 109
- Headquarters
- San Diego, United States
- Website
- arcturusrx.com
ARCT Metrics
BasicAdvanced
$266M
-
-$3.33
2.27
-
Price and volume
Market cap
$266M
Beta
2.27
52-week high
$17.96
52-week low
$5.50
Average daily volume
689K
Financial strength
Current ratio
5.879
Quick ratio
5.764
Long term debt to equity
0.11
Total debt to equity
0.133
Interest coverage (TTM)
-11,366.00%
Profitability
EBITDA (TTM)
-99.548
Gross margin (TTM)
-195.50%
Net profit margin (TTM)
-317.61%
Operating margin (TTM)
-348.32%
Effective tax rate (TTM)
0.00%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-23.96%
Return on equity (TTM)
-46.31%
Valuation
Price to revenue (TTM)
8.936
Price to book
1.55
Price to tangible book (TTM)
1.55
Price to free cash flow (TTM)
-3.604
Free cash flow yield (TTM)
-27.75%
Free cash flow per share (TTM)
-2.597
Growth
Revenue change (TTM)
-75.95%
Earnings per share change (TTM)
49.84%
3-year revenue growth (CAGR)
-51.93%
3-year earnings per share growth (CAGR)
3.97%
What the Analysts think about ARCT
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
Analyst projections of the future price of Arcturus Therapeutics Holdings stock.
ARCT Financial Performance
Revenues and expenses
ARCT Earnings Performance
Company profitability
Upcoming events
No upcoming events
ARCT News
AllArticlesVideos
What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call
MarketBeat6 hours ago
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
MarketBeat1 month ago
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Business Wire1 month ago
Funds containing ARCT
Fund name | Fund size | $ARCT weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 1.52% |
ARK Genomic Revolution£ARCG | $123M | 1.52% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.